We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Test for Chlamydia Antigen Antibodies Optimized

By LabMedica International staff writers
Posted on 07 May 2019
Trachoma, resulting from repeated infection with the bacterium Chlamydia trachomatis (Ct), is the leading infectious cause of blindness. More...
Trachoma is targeted for elimination as a public health problem by 2020.

Serological surveillance for trachoma could allow monitoring of transmission levels in areas that have achieved elimination targets. Platforms that allow testing in basic laboratories or testing of easy-to-manage samples such as dried blood spots would contribute to the feasibility of serologic testing.

An international team of scientists led by the Centers for Disease Control and Prevention (Atlanta, GA, USA) collected blood from 506 1 to 12-year-olds in two villages in Kongwa district, Tanzania. The blood was tested for antibodies against the antigen Pgp3. Whole blood, plasma, and dried blood spots (DBS) were tested in laboratory and field settings using a cassette-enclosed Pgp3 lateral flow assay (LFA-cassette) and a pared-back “dipstick” assay (LFA-dipstick). DBS were also tested with a bead-based multiplex assay (MBA). Pooled ocular swab testing for Ct infection was performed using the GeneXpert CT/NG cartridge.

In the field evaluation of LFA-cassette using whole blood, the percent positive was 42.5% and the sensitivity was 84.2%. In the field evaluation of LFA-cassette using plasma, the percent positive was 48.4% and the sensitivity was 94.7%. The percent agreement between LFA-cassette and LFA-dipstick was 93.8%. The percent agreement between the MBA and each LFA format and sample type ranged from 92.3% to 94.7%. The percent positive by MBA was 45.5%, and the sensitivity was 94.7%. Interrater agreement between an expert rater and three different raters in field and laboratory settings was uniformly good.

The authors concluded that despite the minor differences in individual tests run, there were no significant differences in the percentage of positive samples as determined by MBA or any LFA tests. The data suggest that the LFA, in any number of iterations, and MBA could potentially be used interchangeably in a population-level, programmatic setting based on the program needs. The study was published in the April 2019 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Centers for Disease Control and Prevention


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.